The role of β-adrenoceptor blockers in the treatment of psychiatric disorders

CNS Drugs

Volumn 5, Issue 2, 1996, Pages 115-136

  Bailly, Daniel ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALPRENOLOL; ATENOLOL; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; LITHIUM; METOPROLOL; NADOLOL; OXPRENOLOL; PINDOLOL; PROPRANOLOL; SOTALOL; TIMOLOL;

AGGRESSION; AKATHISIA; ALCOHOLISM; ANXIETY; DYSKINESIA; HUMAN; MENTAL DISEASE; MOOD; OPIATE ADDICTION; PANIC; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TREMOR;

EID: 0030023113     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199605020-00004     Document Type: Review

References (207)

1. Woods PB, Robinson ML. An investigation of the comparative liposolubilities of β-adrenoceptor blocking agents. J Pharm Pharmacol 1981; 33: 172-3
2. Jaillon P, Le Coz F, Sauleman P. Pharmacologie des médicaments β-bloquants. Sem Hôp Paris 1988; 64: 2951-5
3. Dahlöf C, Dimenäs E. Side effects of β-blocker treatments as related to the central nervous system. Am J Med Sci 1990; 299: 236-44
4. Middlemiss DN. Blockade of the central 5-HT autoreceptor by β-adrenoceptor antagonists. Eur J Pharmacol 1986; 120: 51-6
5. Dimsdale JE, Newton RP, Joist T. Neuropsychological side effects of β-blockers. Arch Intern Med 1989; 149: 514-25
6. Dimsdale JE. Reflections on the impact of antihypertensive medications on mood, sedation, and neuropsychologic functioning. Arch Intern Med 1992; 152: 35-9
7. Ananth J, Ling K-M. Propranolol in psychiatry: therapeutic uses and side effects. Neuropsychobiology 1986; 15: 20-7
8. Lader M. β-adrenoceptor antagonists in neuropsychiatry: an update. J Clin Psychiatry 1988; 49: 213-23
9. Koella WP. CNS-related (side-) effects of β-blockers with special reference to mechanisms of action. Eur J Clin Pharmacol 1985; 8 Suppl.: 55-63
10. Kostis JB, Rosen RC. Central nervous system effects of β-adrenergic-blocking drugs: the role of ancillary properties. Circulation 1987; 75: 204-12
11. Blumenthal JA, Madden DJ, Krantz DS, et al. Short-term behavioral effects of β-adrenergic medications in men with mild hypertension. Clin Pharmacol Ther 1988; 4: 429-35
12. Thiessen BQ, Wallace SM, Blackburn JL, et al. Increased prescribing of antidepressants subsequent to beta-blocker therapy. Arch Intern Med 1990; 150: 2286-90
13. Middlemiss DN, Buxton DA, Greenwood DT. Beta-adrenoceptor antagonists in psychiatry and neurology. Pharmacol Ther 1981; 12: 419-37
14. Greenwood DT. Stress, catecholamines, and β-adrenoceptor blockade. Postgrad Med J 1990; 66 Suppl. 2: S36-40
15. Rudd P, Blaschke TF. Antihypertensive agents and the drug therapy of hypertension. In: Gilman AG, Goodman LS, Rall TW, et al., editors. The pharmacological basis of therapeutics. New York: Macmillan Publishing Co., 1985: 784-805
16. Cruickshank JM. How safe are β-blockers? Drugs 1983; 25 Suppl. 2: 331-40
17. Betts TA, Alford C. β-blockers and sleep: a controlled trial. Eur J Clin Pharmacol 1985; 28 Suppl.: 65-8
18. Nahorski SR, Willcocks AL. Interactions of β-adrenoceptor antagonists with 5-hydroxytryptamine receptor subtypes in rat cerebral cortex [abstract]. Br J Pharmacol 1983; 78: 107P
19. Middlemiss DN, Neill J, Tricklebank MD. Subtypes of the 5-HT receptor involved in hypothermia and forepaw treading induced by 8-OH-DPAT [abstract]. Br J Pharmacol 1985; 85: 251P
20. Lesch KP, Poten B, Söhnle K, et al. Pharmacology of the hypothermic response to 5-HT1A receptor activation in humans. Eur J Clin Pharmacol 1990; 39: 17-9
21. Hoyer D. 5-HT receptors: subtypes and second messengers. J Recept Res 1991; 11: 197-214
22. Coltart DJ, Gibson DG, Shand DG. Plasma propranolol levels associated with suppression of ventricular ectopic beats. BMJ 1971; 1: 490-2
23. Lader MH, Tyrer PJ. Central and peripheral effects of propranolol and sotalol in normal human subjects. Br J Pharmacol 1972; 45: 557-60
24. Svenson TH. Peripheral, autonomie regulation of locus coeruleus noradrenergic neurons in brain: putative implications for psychiatry and psychopharmacology. Psychopharmacology 1987; 92: 1-7
25. Johnsson G, Regardh C-G. Clinical pharmacokinetics of β-adrenoceptor blocking drugs. Clin Pharmacokinet 1976; 1: 233-63
26. Lennard MS, Tucker GT, Woods HF. The polymorphic oxidation of β-adrenoceptor antagonists. Clin Pharmacokinet 1986; 11: 1-17
27. Clark DWJ, Morgan AKW, Waal-Manning H. Adverse effects of metoprolol are not generally associated with oxidation status. Br J Clin Pharmacol 1984; 18: 965-7
28. Sporn JR, Molinoff PB. Beta-adrenergic receptors in rat brain. J Cyclic Nucleotide Protein Phosphor Res 1976; 2: 146-61
29. Bylund DB, Snyder SH. Beta-adrenergic receptor binding in membrane preparations from mammalian brain. Mol Pharmacol 1976; 12: 568-80
30. Neill-Dwyer G, Bartlett J, McAinsch J, et al. β-adrenoceptor blockers and the blood-brain barrier. Br J Clin Pharmacol 1981; 11: 549-53
31. Taylor EA, Jefferson D, Carroll JD, et al. Cerebrospinal fluid concentrations of propranolol, pindolol and atenolol in man: evidence for central actions of β-adrenoceptor antagonists. Br J Clin Pharmacol 1981; 12: 549-59
32. Martinez JR, Aguirre R, Calvo R, et al. Decrease in penbutolol central response as a cause of changes in its serum protein binding. J Pharm Pharmacol 1990; 42: 164-6
33. Salem SAM, McDevitt DG. Central effects of single oral doses of atenolol in man. Br J Clin Pharmacol 1984; 17: 31-6
34. Gengo FM, Ermer JC, Carey C, et al. The relationship between serum concentrations and central nervous system actions of metoprolol. J Neurol Neurosurg Psychiatry 1985; 48: 101-6
35. Gengo FM, Huntoon L, McHugh WB. Lipid-soluble and water-soluble β-blockers: comparison of the central nervous system depressant effect. Arch Intern Med 1987; 147: 39-43
36. Nicholson AN, Wright NA, Zetlein MB, et al. Central effects of β-adrenoceptor antagonists. II: Electroencephalogram and body sway. Br J Clin Pharmacol 1988; 26: 129-41
37. Brismar K, Mogensen L, Wetterberg L. Depressed melatonin secretion in patients with nightmares due to β-adrenoceptor blocking drugs. Acta Med Scand 1987; 221: 153-8
38. Granville-Grossman KL, Turner P. The effect of propranolol on anxiety. Lancet 1966; i: 788-90
39. Wheatley D. Comparative effects of propranolol and chlordiazepoxide in anxiety states. Br J Psychiatry 1969; 115: 1411-2
40. Bonn JA, Turner P. D-propranolol and anxiety. Lancet 1971; i: 1355-6
41. Ramsay I, Greer S, Bagley C. Propranolol in neurotic and thyrotoxic anxiety. Br J Psychiatry 1973; 122: 555-60
42. Kellner R, Collins AC, Shulman RS, et al. The short-term anti-anxiety effects of propranolol HCl. J Clin Pharmacol 1974; 14: 301-4
43. Tyrer PJ, Lader MH. Response to propranolol and diazepam in somatic and psychic anxiety. BMJ 1974; 2: 14-6
44. Tanna VT, Penningroth RP, Woolson RF. Propranolol in the treatment of anxiety neurosis. Compr Psychiatry 1977; 18: 319-26
45. Covelli V, Antonaci F, Pagliarulo E, et al. Propranolol: further evidence of its anti-anxiety effects. Acta Ther 1983;9:367-73
46. DeOliveira LLL, De Miranda PSP, Chamos Jr JS. Uso de propranolol no tratamento da ansiedade - um estudo duplo-cego. Folia Med 1983; 86: 83-6
47. Binstok G, Foster LG, Mullane JF. Propranolol and the depression component of anxiety neurosis. Curr Ther Res 1984; 35: 423-32
48. Meibach RC, Dunner D, Wilson LG, et al. Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: a double-blind trial. J Clin Psychiatry 1987; 48: 355-8
49. Meibach RC, Mullane JF, Binstok G. A placebo-controlled multicenter trial of propranolol and chlordiazepoxide in the treatment of anxiety. Curr Ther Res 1987; 41: 65-76
50. Hudson CFE. An evaluation of once daily long acting propranolol hydrochloride (Inderal LA and half-Inderal LA) in the treatment of anxiety. A double-blind placebo controlled general practice study. Br J Clin Pract 1988; 42: 419-26
51. Saul P, Jones BP, Edwards KG. Randomized comparison of atenolol and placebo in the treatment of anxiety: a double-blind study. Eur J Clin Pharmacol 1985; 28 Suppl: 109-10
52. Peet M, Ali S. Propranolol and atenolol in the treatment of anxiety. Int Clin Psychopharmacol 1986; 1: 314-9
53. Silverstone JT. Some new approaches to the treatment of anxiety. Psychopharmacol Bull 1974; 10: 10-1
54. Becker AL. Oxprenolol and propranolol in anxiety states: a double-blind comparative study. S Afr Med J 1976; 50: 627-9
55. Burrows GD, Davies B, Fail L, et al. A placebo controlled trial of diazepam and oxprenolol for anxiety. Psychopharmacology 1976; 50: 177-9
56. Johnson G, Singh B, Leeman M. Controlled evaluation of the beta-adreno-receptor blocking drug oxprenolol in anxiety. Med J Aust 1976; 1: 902-12
57. Bonn JA, Turner P, Hicks DC. Beta-adrenergic-receptor blockade with practolol in treatment of anxiety. Lancet 1972; i: 814-5
58. Tyrer PJ, Lader MH. Effects of beta-adrenergic blockade with sotalol in chronic anxiety. Clin Pharmacol Ther 1973; 14: 418-26
59. Dubovsky SL. Generalised anxiety disorder: new concepts and psychopharmacologic therapies. J Clin Psychiatry 1990; 51 Suppl. 1: 3-10
60. Kathol RG, Noyes R, Slymen DJ, et al. Propranolol in chronic anxiety disorders. Arch Gen Psychiatry 1980; 37: 1361-5
61. Hallstrom C, Treasaden I, Guy Edwards J, et al. Diazepam, propranolol and their combination in the management of chronic anxiety. Br J Psychiatry 1981; 139: 417-21
62. Munjack DJ, Crocker B, Cabe D, et al. Alprazolam, propranolol and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 1989; 9: 22-7
63. Noyes R, Anderson DJ, Clancy J, et al. Diazepam and propranolol in panic disorder and agoraphobia. Arch Gen Psychiatry 1984; 41: 287-92
64. Munjack DJ, Rebal R, Shaner R, et al. Imipramine versus propranolol for the treatment of panic attacks: a pilot study. Compr Psychiatry 1985; 26: 80-9
65. Gorman JM, Levy GF, Liebowitz MR, et al. Effect of acute beta-adrenergic blockade on lactate-induced panic. Arch Gen Psychiatry 1983; 40: 1079-82
66. Shehi M, Patterson WM. Treatment of panic attacks with alprazolam and propranolol. Am J Psychiatry 1984; 141: 900-1
67. Suzman MM. The use of beta-adrenergic blockade with propranolol in anxiety syndromes. Postgrad Med J 1971; 47 Suppl.: 104-7
68. Joorabchi B. Expressions of the hyperventilation syndrome in childhood. Clin Pediatr (Phila) 1977; 16: 1110-5
69. Folgering H, Rutten H, Roumen Y. Beta-blockade in the hyperventilation syndrome: a retrospective assessment of symptoms and complaints. Respiration 1983; 44: 19-25
70. Feline A. Les bêta-bloquants dans l'anxiété. Psychiatrie 1986; 3 Suppl.: 124-9
71. Brewer C. Beneficial effect of beta-adrenergic blockade on 'exam nerves'. Lancet 1972; ii: 435
72. Brantigan TA, Brantigan CO, Joseph N. Beta-blockade and musical performance. Lancet 1978; ii: 896
73. Brantigan CO, Brantigan TA, Joseph N. Effects of beta-blockade and beta-stimulation on stage fright. Am J Med 1982; 72: 88-94
74. Hartley LR, Ungapen S, Davies I, et al. The effect of beta-adrenergic blocking drugs on speaker's performance and memory. Br J Psychiatry 1983; 142: 512-7
75. Drew PJT, Barnes JN, Evans SJW. The effect of acute β-adrenoceptor blockade on examination performance. Br J Clin Pharmacol 1985; 19: 783-6
76. James IM, Pearson RM, Griffiths DNW, et al. Effect of oxprenolol on stage-fright in musicians. Lancet 1977; ii: 952-4
77. Landauer AA, Pocock DA. Stress reduction by oxprenolol and placebo: controlled investigation of the pharmacological and non-specific effects. BMJ 1984; 289: 592
78. Gates GA, Saegert J, Wilson N, et al. Effect of beta blockade on singing performance. Ann Otol Rhinol Laryngol 1985; 94: 570-4
79. James I, Savage I. Beneficial effect of nadolol on anxiety-induced disturbances of performance in musicians: a comparison with diazepam and placebo. Am Heart J 1984; 108: 1150-5
80. McMillin WP. Oxprenolol in the treatment of anxiety due to environmental stress. Am J Psychiatry 1975; 132: 965-8
81. Faustman WO, White PA. Diagnostic and psychopharmacological treatment characteristics of 536 inpatients with posttraumatic stress disorder. J Nerv Ment Dis 1989; 177: 154-9
82. Kolb LC, Burris BC, Griffiths S. Propranolol and clonidine in the treatment of post-traumatic stress disorders of war. In: Van der Kolk BA, editor. Post-traumatic stress disorder: psychological and biological sequelae. Washington, DC: American Psychiatric Press, 1984: 97-107
83. Famularo R, Kinscherff R, Fenton T. Propranolol treatment for childhood post traumatic stress disorder, acute type. Am J Dis Child 1988; 142: 1244-7
84. Gorman JM, Gorman LK. Drug treatment of social phobias. J Affect Disord 1987; 13: 183-92
85. Falloon IR, Lloyd GG, Harpin R. The treatment of social phobia: real-life rehearsal with nonprofessional therapists. J Nerv Ment Dis 1981; 169: 180-4
86. Gorman JM, Liebowitz MR, Fyer AJ, et al. Treatment of social phobia with atenolol. J Clin Psychopharmacol 1985; 5: 298-301
87. Liebowitz MR, Gorman JM, Fyer AJ, et al. Pharmacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol. J Clin Psychiatry 1988; 49: 252-7
88. Hafner J, Milton F. The influence of propranolol on the exposure in vivo of agoraphobics. Psychol Med 1977; 7: 417-25
89. Fagerstrom KO, Hugdall K, Lundstrom N. Effect of beta-receptor blockade on anxiety with reference to the three-systems model of phobic behavior. Neuropsychobiology 1985; 13: 187-93
90. Tyrer P. Current status of β-blocking drugs in the treatment of anxiety disorders. Drugs 1988; 36: 773-83
91. American Psychiatric Association. Diagnostic and statistic manual of mental disorders. 3rd ed. rev. Washington, DC: American Psychiatric Association, 1987
92. Laverdure B, Boulenger JP. Médications bèta-bloquantes et anxiété. Un intérêt thérapeutique certain. Encéphale 1991; XVII: 481-92
93. Quality Assurance Project. Treatment outlines for the management of anxiety states. Aust NZ J Psychiatry 1985; 19: 138-51
94. Frohlich ED, Dunstan HP, Page IH. Hyperdynamic beta-adrenergic circulatory state. Arch Intern Med 1966; 117: 614-9
95. Marsden CW. Propranolol in neurocirculatory asthenia and anxiety. Postgrad Med J 1971; 47 Suppl.: 100-3
96. Nordenfelt I, Persson S, Redfors A. Effect of a new adrenergic beta-blocking agent, H 56-28, on nervous heart complaints. Acta Med Scand 1968; 184: 465-71
97. Le Van D, Mayeux D, Kohler Ch, et al. Hypertonie bêta-adrénergique dans les manifestations psychosomatiques de l'anxiété et effet thérapeutique d'un bêta-bloquant cardiosélectif: le bétaxolol. Thérapie 1988; 43: 451-6
98. Al-Qassab H, Cleeves LA, Francis PL, et al. Is there a central nervous withdrawal syndrome associated with discontinuing long term treatment with propranolol? Hum Toxicol 1988; 7: 249-54
99. Guthrie SK. The treatment of alcohol withdrawal. Pharmacotherapy 1989; 9: 131-43
100. Parquet PhJ, Bailly D. Le traitement du sevrage alcoolique. Neuro-Psy 1989; 4: 335-46
101. Whitfield CL, Thompson G, Lamb A, et al. Detoxification of 1024 alcoholic patients without psychoactive drugs. JAMA 1978; 239: 1409-10
102. Shaw JM, Kolesar GS, Sellers EM, et al. Development of optimal treatment tactics for alcohol withdrawal. I: Assessment and effectiveness of supportive care. J Clin Psychopharmacol 1981; 1: 382-7
103. Naranjo CA, Sellers EM, Chater K, et al. Nonpharmacologic intervention in acute alcohol withdrawal. Clin Pharmacol Ther 1983; 34: 214-9
104. Bailly D, Pinson Ph, Moreau-Meresse K, et al. La place des psychotropes dans le sevrage alcoolique. Etude préliminaire. Bull Soc Franç Alcool 1987; 9: 14-20
105. American Psychiatric Association. Diagnostic and statistic manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
106. Zilm DH, Sellers EM, Mac Leod SM, et al. Propranolol effect on tremor in alcoholic withdrawal. Ann Intern Med 1975; 83: 234-6
107. Kraus ML, Gottlieb LD, Horwitz RI, et al. Randomized clinical trial of atenolol in patients with alcohol withdrawal. N Engl J Med 1985; 313: 905-9
108. Horwitz RI, Gottlieb LD, Kraus ML. The efficacy of atenolol in the outpatient management of the alcohol withdrawal syndrome. Results of a randomized clinical trial. Arch Intern Med 1989; 149: 1089-93
109. Sellers EM, Zilm DH, Degani NC. Comparative efficacy of propranolol and chlordiazepoxide in alcohol withdrawal. J Stud Alcohol 1977; 38: 2096-108
110. Zilm DH, Jacob MS, MacLeod SM, et al. Propranolol and chlordiazepoxide effects on cardiac arrhythmias during alcohol withdrawal. Alcohol Clin Exp Res 1980; 4: 400-5
111. Bailly D, Servant D, Blandin N, et al. Effects of beta-blocking drugs in alcohol withdrawal: a double-blind comparative study with propranolol and diazepam. Biomed Pharmacother 1992;46:419-24
112. Potter JF, Bannan LT, Beevers DG. The effect of a non-selective lipophilic beta-blocker on the blood pressure and noradrenaline, vasopressin, cortisol and renin release during alcohol withdrawal. Clin Exper Hypertens 1984; 6: 1147-60
113. Carlsson C, Häggendal J. Arterial noradrenaline levels after ethanol withdrawal. Lancet 1967; ii: 889
114. Carlsson C, Johansson T. The psychological effects of propranolol in the abstinence phase of chronic alcoholics. Br J Psychiatry 1971; 119: 605-6
115. Gottlieb LD, Horwitz RI, Kraus ML, et al. Randomized controlled trial in alcohol relapse prevention: role of atenolol, alcohol craving, and treatment adherence. J Subst Abuse Treat 1994; 11: 253-8
116. Bailly D, Georget O, Houdret N, et al. Alcoolisme et toxicomanie: données socio-démographiques et toxicologiques. Sem Hôp Paris 1990; 66: 2448-54
117. Tyrer P, Rutherford D, Huggett T. Benzodiazepine withdrawal symptoms and propranolol. Lancet 1981; i: 520-2
118. Owen RT, Tyrer P. Benzodiazepine dependence - a review of the evidence. Drugs 1983; 25: 385-98
119. Tyrer P, Owen R, Dawning S. Gradual withdrawal of diazepam after long-term therapy. Lancet 1983; i: 1402-6
120. Rickels K, Case GW, Winokur A, et al. Long-term benzodiazepine therapy: benefits and risks. Psychopharmacol Bull 1984; 20: 608-15
121. Tyrer P. Dependence as a limiting factor in the clinical use of minor tranquillisers. Pharmacol Ther 1988; 36: 173-88
122. Grosz HJ. Narcotic withdrawal symptoms in heroin users treated with propranolol. Lancet 1972; ii: 564-6
123. Grosz HJ. The effect of propranolol on active users of heroin. Lancet 1973; ii: 602
124. Lowenstein H. Propranolol as a psychotropic agent. Lancet 1973; 1: 559
125. Hollister LE, Prusmack JJ. Propranolol in withdrawal from opiates. Arch Gen Psychiatry 1974; 31: 695-8
126. Elliott FA. Propranolol for the control of belligerent behavior following acute brain damage. Ann Neurol 1977; 1: 489-91
127. Schreier HA. Use of propranolol in the treatment of post-encephalitic psychosis. Am J Psychiatry 1979; 136: 840-1
128. Mansheim P. Treatment with propranolol of the behavioral sequelae of brain damage [letter]. J Clin Psychiatry 1981; 42: 132
129. Petrie WM, Ban TA. Propranolol in organic agitation [letter]. Lancet 1981; i: 324
130. Yudofsky S, Williams D, Gorman J. Propranolol in the treatment of rage and violent behavior in patients with chronic brain syndromes. Am J Psychiatry 1981; 138: 218-20
131. Reynols EH. The pharmacological management of epilepsy associated with psychological disorders. Br J Psychiatry 1982; 141: 549-57
132. Williams DT, Mehl R, Yudofsky S, et al. The effect of propranolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction. J Am Acad Child Psychiatry 1982; 21: 129-35
133. Leon Z, Alonso JL, Basterrechea L. Acción del propranolol en la agresividad de los oligofrénicos encefalopáticos. J Int Defectología en el Hogar de Impedidos Físicos y Mentales 1983; 4: 431-6
134. Ratey JJ, Morrill R, Oxenkrug G. Use of propranolol for provoked and unprovoked episodes of rage. Am J Psychiatry 1983; 140: 1356-7
135. Greendyke RM, Schuster DB, Wooton JA. Propranolol in the treatment of assaultive patients with organic brain disease. J Clin Psychopharmacol 1984; 4: 282-5
136. Yudofsky S, Stevens L, Silver J, et al. Propranolol in the treatment of rage and violent behavior associated with Korsakoff's psychosis. Am J Psychiatry 1984; 141: 114-5
137. Greendyke RM, Kanter DR, Schuster DB, et al. Propranolol treatment of assaultive patients with organic brain disease: a double-blind crossover, placebo-controlled study. J Nerv Ment Dis 1986; 174: 290-4
138. Ratey JJ, Mikkelsen EJ, Smith GB, et al. Beta-blockers in the severely and profoundly mentally retarded. J Clin Psychopharmacol 1986; 6: 103-7
139. Jenkins SC, Maruta T. Therapeutic use of propranolol for intermittent explosive disorder. Mayo Clin Proc 1987; 62: 204-14
140. Lang C, Remington D. Treatment with propranolol of severe self-injurious behavior in a blind, deaf, retarded adolescent. J Am Acad Child Adolesc Psychiatry 1994; 33: 265-9
141. Mattes JA. Metoprolol for intermittent explosive disorder. Am J Psychiatry 1985; 142: 1108-9
142. Polakoff SA, Sorgi PJ, Ratey JJ. The treatment of impulsive and aggressive behavior with nadolol [letter]. J Clin Psychopharmacol 1986; 6: 125-6
143. Greendyke RM, Kanter DR. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double blind study. J Clin Psychiatry 1986; 47: 423-6
144. Greendyke RM, Berkner JP, Webster JC, et al. Treatment of behavioral problems with pindolol. Psychosomatics 1989; 30: 161-5
145. Kuperman S, Stewart MA. Use of propranolol to decrease aggressive outbursts in younger patients. Psychosomatics 1987; 28: 315-9
146. Grizenko N, Vida S. Propranolol treatment of episodic dyscontrol and aggressive behavior in children [letter]. Can J Psychiatry 1988; 33: 776-8
147. Mattes JA, Rosenberg J, Mays D. Carbamazepine versus propranolol in patients with uncontrolled rage outbursts: a random assignment study. Psychopharmacol Bull 1984; 20: 98-100
148. Luchins DJ, Dojka D. Lithium and propranolol in aggression and self-injurious behavior in the mentally retarded. Psychopharmacol Bull 1989; 25: 372-5
149. Stewart JT. Paradoxical aggressive effect of propranolol in a patient with Huntington's disease. J Clin Psychiatry 1987; 48: 385-6
150. Sheppard GP. High-dose propranolol in schizophrenia. Br J Psychiatry 1979; 134: 470-6
151. Pugh CR, Steinert J, Priest RG. Propranolol in schizophrenia: a double blind, placebo controlled trial of propranolol as an adjunct to neuroleptic medication. Br J Psychiatry 1983; 143: 151-5
152. Sorgi PJ, Ratey JJ, Polakoff S. β-adrenergic blockers for the control of aggressive behaviors in patients with chronic schizophrenia. Am J Psychiatry 1986; 143: 775-6
153. Whitman JR, Maier GT, Eichelman B. Beta-blockers for aggressive behavior in schizophrenia. Am J Psychiatry 1987; 144: 538
154. Ratey JJ, Bemporad J, Sorgi P, et al. Open trial effects of beta-blockers on speech and social behaviors in 8 autistic adults. J Autism Dev Disord 1987; 17: 439-46
155. Ritrovato CA, Weber SS, Dufresne RL. Nadolol in the treatment of aggressive behavior associated with schizophrenia. Clin Pharmacol 1989; 8: 132-5
156. Alpert M, Allan ER, Citrome L, et al. A double blind placebo controlled study of adjunctive nadolol in the management of violent psychiatric patients. Psychopharmacol Bull 1990; 26: 367-71
157. Peet M, Middlemiss DN, Yates RA. Propranolol in schizophrenia. II: Clinical and biochemical aspects of combining propranolol with chlorpromazine. Br J Psychiatry 1981; 139: 112-7
158. Silver JM, Yudofsky SC, Kogan M, et al. Elevation of thioridazine plasma levels by propranolol. Am J Psychiatry 1986; 143: 1290-2
159. Ratey JJ, Lindem KJ. β-blockers as primary treatment for aggression and self-injury in the developmentally disabled. In: Ratey JJ, editor. Mental retardation developing pharmacotherapies. Washington, DC: American Psychiatric Press, 1991: 51-81
160. Mattes JA. Psychopharmacology of temper outbursts: a review. J Nerv Ment Dis 1986; 174: 464-70
161. Bainbridge JG, Greenwood DT. The tranquilizing effects of propranolol demonstrated in rats. Neuropharmacology 1971; 10: 453-8
162. Smith DA, Perry PJ. Nonneuroleptic treatment of disruptive behavior in organic mental syndromes. Ann Pharmacother 1992; 26: 1400-8
163. Atsmon A, Blum I, Wijsenbeek H, et al. The short-term effects of adrenergic-blocking agents in a small group of psychotic-patients. Psychiatr Neurol Neurochir 1971; 74: 251-8
164. Atsmon A, Blum I, Steiner M, et al. Further studies with propranolol in psychotic patients: relation to initial psychiatric state, urinary catecholamines and 3-methoxy-4-hydroxy-phenylglycol excretion. Psychopharmacologia 1472; 27: 249-54
165. Yorkston NJ, Zaki SA, Malik MKU, et al. Propranolol in the control of schizophrenic symptoms. BMJ 1974; 14: 633-5
166. Yorkston NJ, Gruzelier JH, Zaki SA, et al. Propranolol as an adjunct to the treatment of schizophrenia. Lancet 1977; ii: 575-8
167. Elizur A, Segal Z, Yeret A, et al. Antipsychotic effect of propranolol on chronic schizophrenics: study of a gradual treatment regimen. Psychopharmacology 1979; 60: 189-94
168. Eccleston D, Fairbairn AF, Hassanyeb F, et al. The effect of propranolol and thioridazine on positive and negative symptoms of schizophrenia. Br J Psychiatry 1985; 147: 623-30
169. Gardos G, Cole JO, Volicer L, et al. A dose-response study of propranolol in chronic schizophrenics. Curr Ther Res 1973; 15: 314-23
170. Myers DH, Campbell PL, Cocks NM, et al. A trial of propranolol in chronic schizophrenia. Br J Psychiatry 1981; 139: 118-21
171. Peet M, Bethell MS, Coates A, et al. Propranolol in schizophrenia. 1: Comparison of propranolol, chlorpromazine and placebo. Br J Psychiatry 1981; 139: 105-11
172. Manchanda R, Hirsch SR. Does propranolol have an antipsychotic effect? A placebo-controlled study in acute schizophrenia. Br J Psychiatry 1986; 148: 701-7
173. Hanssen T, Heyden T, Sundberg I, et al. Propranolol in schizophrenia: clinical, metabolic and pharmacological findings. Arch Gen Psychiatry 1980; 37: 685-90
174. Rosenthal NE, Jacobsen FM, Sack DA, et al. Atenolol in seasonal affective disorder: a test of the melatonin hypothesis. Am J Psychiatry 1988; 145: 52-6
175. Schlager DS. Early-morning administration of short-acting β-blockers for treatment of winter depression. Am J Psychiatry 1994; 151: 1383-5
176. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994; 51: 248-51
177. Hjorth S. Serotonin 5-HT1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. J Neurochem 1992; 60: 776-9
178. Gillette DW, Tannery LP. β-blocker inhibits tricyclic metabolism. J Am Acad Child Adolesc Psychiatry 1994; 33: 223-4
179. Strang RR. The symptom of restless legs. Med J Aust 1967; 24: 1211-3
180. Lipinski JF, Zubenko GS, Barriera P, et al. Propranolol in the treatment of neuroleptic-induced akathisia. Lancet 1983; ii: 685-6
181. Kulik AV, Wilbur R. Case report of propranolol (Inderal) pharmacotherapy for neuroleptic-induced akathisia and tremor. Prog Neuropsychopharmacol Biol Psychiatry 1983; 7: 223-5
182. Lipinski JF, Zubenko GS, Cohen BM, et al. Propranolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1984; 141: 412-5
183. Adler L, Angrist B, Peselow E, et al. Efficacy of propranolol in neuroleptic-induced akathisia. J Clin Psychopharmacol 1985; 5: 164-6
184. Adler L, Angrist B, Peselow E, et al. A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry 1986; 149: 42-5
185. Adler LA, Reiter S, Corwin J, et al. Differential effects of benztropine and propranolol in akathisia. Psychopharmacol Bull 1987; 23: 519-21
186. Derom E, Elinck W, Buylaert W, et al. Which beta-blocker for the restless leg [letter]? Lancet 1984; i: 857
187. Reiter S, Adler L, Angrist B, et al. Atenolol and propranolol in neuroleptic-induced akathisia. J Clin Psychopharmacol 1987; 7: 279-80
188. Dupuis B, Catteau J, Dumon JP, et al. Comparison of propranolol, sotalol, and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1987; 144: 802-5
189. Dumon JP, Catteau J, Lanvin F, et al. Randomized, double-blind, crossover, placebo-controlled comparison of propranolol and hetaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 1992; 149: 647-50
190. Zubenko GS, Lipinski JF, Cohen BM, et al. Comparison of metoprolol and propranolol in the treatment of akathisia. Psychiatr Res 1984; 11: 143-8
191. Kim A, Adler A, Angrist B, et al. Efficacy of low-dose metoprolol in neuroleptic-induced akathisia. J Clin Psychopharmacol 1989; 9: 294-6
192. Ratey JJ, Sorgi P, Polakoff S. Nadolol as a treatment for akathisia. Am J Psychiatry 1985; 142: 640-2
193. Adler LA, Angrist B, Weinreb H, et al. Studies on the time course and efficacy of β-blockers in neuroleptic-induced akathisia and the akathisia of idiopathic Parkinson's disease. Psychopharmacol Bull 1991; 27: 107-11
194. Adler LA, Reiter S, Angrist B, et al. Pindolol and propranolol in neuroleptic-induced akathisia. Am J Psychiatry 1987; 144: 1241-2
195. Reiter S, Adler L, Erle S, et al. Neuroleptic-induced akathisia treated with pindolol. Am J Psychiatry 1987; 144: 383-4
196. Beta-adrenoreceptor antagonists in essential tremor [editorial]. Lancet 1983; ii: 1234-5
197. Kirk L, Baastrup PC, Schou M. Propranolol treatment of lithium induced tremor. Lancet 1973; ii: 1086-7
198. Young RR, Shahani BT. Pharmacology of tremor. Clin Neuropharmacol 1979; 4: 139-56
199. Floru L, Floru L, Tegeler J. Therapeutische bedeutung der β-rezeptorenblockade bei lithiumbedingtem tremor. Behandlungsversuche mit pindolol und practolol. Med Welt 1974; 25: 450-2
200. Gaby NS, Lefkowitz DS, Israel JR. Treatment of lithium tremor with metoprolol. Am J Psychiatry 1983; 140: 593-5
201. Davé M. Treatment of lithium induced tremor with atenolol. Can J Psychiatry 1989; 34: 132-3
202. Moreira MJC, Karnio IG. Improvement of tardive dyskinesia with high doses of propranolol: a case report. Rev Paul Med 1979; 93: 76-8
203. Bacher NM, Lewis HA. Low-dose propranolol in tardive dyskinesia. Am J Psychiatry 1980; 137: 495-7
204. Kulik FA, Wilbur R. Propranolol for tardive dyskinesia and extrapyramidal side effects (pseudoparkinsonism) from neuroleptics. Psychopharmacol Bull 1980; 16: 18-9
205. Perenyi A, Farkas A. Propranolol in the treatment of tardive dyskinesia. Biol Psychiatry 1983; 18: 391-4
206. Jeste DV, Wyatt RJ. Understanding and treating tardive dyskinesia. New York: Guilford Press, 1982
207. Yassa R, Iskandar H, Nastase C. Propranolol in the treatment of tardive akathisia: a report of two cases. J Clin Psychopharmacol 1988; 8: 283-5